Want to see FEMY full AI Analyst Report?
Femasys (FEMY) Stock Price & Analysis
FEMY Stock Chart & Stats
- Day’s Range
- $1.30 - $1.41
- 52-Week Range
- $1.26 - $22.22
- Previous Close
- $1.31
- Volume
- N/A
- Average Volume (3M)
- 112.58K
- Market Cap
- $11.47M
- Enterprise Value
- $17.38M
- Total Cash (Recent Filing)
- $1.44M
- Total Debt (Recent Filing)
- $4.79M
- Price to Earnings (P/E)
- ―
- Beta
- 0.57
- Next Earnings
- Nov 17, 2026 (Est.)
- EPS Estimate
- -0.6
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Capital Infusion
The $30 million financing strengthens near-term liquidity relative to the company’s substantial cash burn and provides resources to continue developing and commercializing its women’s-health technologies. It may reduce immediate funding pressure over the next several quarters, although warrants can increase dilution.
Gross Margin
A roughly 50% gross margin indicates that the company’s products retain meaningful economic value after direct costs, providing a foundation for improved operating leverage if revenue scales. This underlying margin profile is constructive, although current losses remain far too large for the revenue base.
Board Governance
The appointment adds an independent director with Audit and Compensation Committee responsibilities, supporting formal oversight as the company deploys new capital and develops its commercial strategy. A defined term through 2029 also provides continuity in board-level governance during execution.
Bears Say
Severe Unprofitability
The company is generating losses several times larger than its revenue, showing that its current operating structure has not reached viable scale. Until revenue expands materially or expenses fall, this level of unprofitability will continue to consume capital and constrain strategic flexibility.
Persistent Cash Burn
Heavy operating and free-cash-flow deficits indicate that the business cannot currently fund its activities from internally generated cash. Continued burn increases reliance on external financing, and the absolute outflow remains substantial relative to the company’s approximately $2.3 million revenue base.
Balance-sheet Deterioration
Higher leverage combined with sharply reduced equity weakens financial flexibility and increases dependence on financing to support operations. The deterioration also reflects cumulative losses, leaving a smaller capital buffer to absorb execution setbacks or fund expansion without further shareholder impact.
Femasys News
Femasys announces Minnesota Women’s Care to implement FemVue
Femasys (FEMY) announced that Minnesota Women’s Care will implement FemVue for fertility diagnostic evaluation and FemaSeed Complete for in-office first-line fertility treatment across its four OB/GYN practice locations. Published first
Femasys announces FDA approval of FemBloc modular premarket approval application
Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational non-surgical permanent birth control technology in the United States. FemBloc is
FEMY FAQ
What was Femasys’s price range in the past 12 months?
What is Femasys’s market cap?
When is Femasys’s upcoming earnings report date?
How were Femasys’s earnings last quarter?
Is Femasys overvalued?
Does Femasys pay dividends?
What is Femasys’s EPS estimate?
How many shares outstanding does Femasys have?
What happened to Femasys’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Femasys?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Femasys
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Kathy Lee-Sepsick
- Employees
- 53
- Website
- www.femasys.com
- Address
- 3950 Johns Creek Court, Suwanee, GA, 30024, US
Femasys (FEMY) Earnings & Revenues
FEMY Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 1 | 0 | 11 |










